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Serum vascular cell adhesion molecule-1 predicts signiﬁcant
liver ﬁbrosis in non-alcoholic fatty liver disease
S Lefere1, F Van de Velde2, L Devisscher1, M Bekaert2, S Raevens1, X Verhelst1, Y Van Nieuwenhove3, M Praet4, A Hoorens4,
C Van Steenkiste1,5, H Van Vlierberghe1, B Lapauw2 and A Geerts1
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide and is strongly
associated with obesity, dyslipidemia and insulin resistance. NAFLD often presents as simple steatosis (NAFL) but can progress to
non-alcoholic steatohepatitis (NASH) and ﬁbrosis. Current non-invasive biomarkers are not tailored to identify signiﬁcant (⩾ F2)
ﬁbrosis, although recent guidelines recommend a stringent follow-up of this patient population. We and others have reported on
the role of pathological angiogenesis in the pathogenesis of NAFLD, highlighting pro-angiogenic factors as potential diagnostic
markers.
OBJECTIVE: To investigate the applicability of angiogenic and endothelial dysfunction markers as non-invasive diagnostic tools for
NASH or NASH-associated ﬁbrosis in obese patients.
METHODS: In a prospective cross-sectional study, male patients undergoing bariatric surgery (n= 61) and control patients (n= 35)
were recruited. Serum protein levels and visceral adipose tissue gene expression of endothelial dysfunction and angiogenic markers
were analyzed by multiplex bead-based assay and quantitative RT-PCR, respectively. For validation, we recruited a second cohort of
patients undergoing bariatric surgery (n= 40) and a cohort of NAFLD patients from our outpatient clinic (n= 30).
RESULTS: We identiﬁed serum vascular cell adhesion molecule-1 (VCAM-1) as an independent predictor for ⩾ F2 ﬁbrosis (median
14.0 vs 8.7 ng ml−1 in patients with and without signiﬁcant ﬁbrosis; Po0.0001) with an area under the receiver-operating
characteristics (AUROC) curve of 0.80. The cutoff point of 13.2 ng ml− 1 showed a sensitivity of 80% and speciﬁcity of 83%. In line
with these results, VCAM-1 visceral adipose tissue gene expression was also elevated in patients with ﬁbrosis (P= 0.030). In the
bariatric surgery and clinical validation cohorts, VCAM-1 displayed similar AUROCs of 0.89 and 0.85, respectively.
CONCLUSIONS: VCAM-1 levels are able to accurately predict signiﬁcant (⩾ F2) ﬁbrosis in NAFLD patients.
International Journal of Obesity (2017) 41, 1207–1213; doi:10.1038/ijo.2017.102
INTRODUCTION
As a result of the obesity pandemic, non-alcoholic fatty liver
disease (NAFLD) has become the most common cause of chronic
liver disease worldwide. NAFLD is the hepatic manifestation of
obesity and a precursor of and independent risk factor for type 2
diabetes.1–3 NAFLD comprises a spectrum of disease that ranges
from hepatocellular steatosis without necro-inﬂammation (NAFL)
to non-alcoholic steatohepatitis (NASH), ﬁbrosis, cirrhosis and
even hepatocellular carcinoma. In addition, NAFLD is an indepen-
dent risk factor for cardiovascular disease, with recent studies
unequivocally showing an increased cardiovascular mortality in
NAFLD patients.4,5 The global prevalence of NAFLD and NASH is
around 25% and 3%, respectively, although this rises to an
estimated 90% and 25%, respectively, in severely obese
patients.3,6
Liver biopsy is still considered as the gold standard for the
diagnosis of NASH and the assessment of disease activity and
ﬁbrosis, although it has important disadvantages such as its high
cost, invasive nature and the risk of sampling error.7 This has
inspired the search for non-invasive disease markers, including
both serum biomarkers and imaging methods. Nevertheless, there
are currently no non-invasive markers that can adequately
distinguish NAFL from NASH.8 Similarly, while many markers have
shown an acceptable accuracy for the exclusion of advanced
ﬁbrosis/cirrhosis (F3-F4),9,10 the identiﬁcation of advanced disease
is less accurate, and the distinction between signiﬁcant (⩾ F2) or
any (⩾ F1) ﬁbrosis vs no ﬁbrosis remains difﬁcult.7,9 The latter
represents an unmet need, as recent guidelines recommend a
closer follow-up of patients with signiﬁcant ﬁbrosis,7 and the long-
term prognosis of patients with ﬁbrosis, even F1, is worse
compared to NAFLD patients without ﬁbrosis.5
The progression of NAFL to NASH, ﬁbrosis and cirrhosis has
previously been linked to endothelial dysfunction and pathologi-
cal angiogenesis. Indeed, NAFLD strongly associates with various
indices of endothelial dysfunction, such as a reduced brachial
artery ﬂow-mediated vasodilatation and a lower peripheral
tonometry ratio.11,12 Increases in serum levels of soluble markers
of endothelial dysfunction and atherosclerosis, such as asym-
metric dimethyl arginine and plasminogen activator inhibitor 1,
have been reported in patients with NAFLD.13,14 Similarly, neo-
angiogenesis is increased in NASH patients and correlates with the
severity of ﬁbrosis.15 Research in animal models has suggested a
role for vascular endothelial growth factor (VEGF)-coordinated
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angiogenesis in ﬁbrosis progression.16 Our group has subse-
quently demonstrated that treatment with anti-VEGF antibodies
reduced experimental steatohepatitis.17 Endothelial dysfunction
and pathological angiogenesis in turn predispose the liver to
further injury as they increased intrahepatic vascular resistance,
distorted the sinusoidal microvascular architecture, modulated
leukocyte inﬁltration and caused local tissue hypoxia.17–19 Indeed,
both processes seem to be early events that precede the
development of inﬂammation and ﬁbrosis18,20 and further
substantiate the links between NAFLD and cardiovascular
disease.21 As such, angiogenesis and endothelial dysfunction are
important mediators of NAFLD progression, although their role as
diagnostic markers has not been thoroughly investigated.
Therefore, we investigated whether markers of endothelial
dysfunction and angiogenesis could distinguish between various
NAFLD disease stages in a well-characterized cohort of severely
obese men undergoing bariatric surgery. Our results point to
vascular cell adhesion molecule 1 (VCAM-1) as a promising marker
for ⩾ F2 ﬁbrosis. We have validated these ﬁndings in an
independent cohort of patients undergoing bariatric surgery,
and in a cohort of outpatients with NAFLD recruited in our
outpatient hepatology clinic.
PATIENTS AND METHODS
Patient cohort
A cohort of 61 consecutive male patients scheduled for bariatric
surgery was recruited at the Ghent University Hospital between
2011 and 2016 within the context of a previous study.22 All obese
patients had biopsy-conﬁrmed NAFLD. Appropriate exclusion of
liver disease of other etiologies, including alcohol-induced or
drug-induced liver disease, viral or auto-immune hepatitis,
metabolic and cholestatic liver diseases, was performed using
speciﬁc clinical, biochemical, histological and/or radiographic
criteria. All patients had a negative history of alcohol abuse as
indicated by an average daily consumption of ⩽20 g. None of the
subjects were on treatment with corticosteroids or insulin, while
other oral glucose-lowering medications were discontinued
before surgery. For comparison, 35 non-obese male controls were
recruited. These were healthy volunteers (n= 17) or patients who
underwent elective abdominal surgery for adhaesiolysis, hernia
diaphragmatica, sigmoidectomy or Nissen fundoplication (n= 18).
All control subjects had an overall good health, with normal
results on liver function tests (patients with aspartate amino-
transferase (AST), alanine aminotransferase (ALT) 41.5 times the
upper normal value for 3 months or longer were excluded) and a
negative history of alcohol abuse.
Blood samples were collected from patients and controls after
overnight fasting, before surgery. All samples were centrifuged,
fractionated and stored at − 80 °C until further analysis. Liver and
visceral adipose tissue (VAT) biopsies were obtained only in those
patients undergoing bariatric surgery. Laboratory evaluation
included standard liver biochemistry (ALT, AST, γ-glutamyl
transpeptidase (GGT)), complete blood count, triglycerides, high-
density lipoprotein (HDL) cholesterol, low-density lipoprotein
(LDL) cholesterol and total serum cholesterol, glucose and insulin.
Cytokeratin (CK)-18 M30 fragments were measured using the M30
apoptosense ELISA kit (TECOmedical, Nijkerk, The Netherlands).
Anthropometric measurements were performed during a pre-
operative examination. Body weight was measured to an accuracy
of 0.1 kg in light indoor clothing without shoes, and height was
measured using a wall-mounted stadiometer. Body mass index
(BMI) was calculated as body weight/height2 (kg m− 2). Waist
circumference was measured at the umbilicus. Insulin resistance
was estimated by calculating the homeostasis model assessment-
insulin resistance (HOMA-IR) using the formula: Insulin
(μU ml− 1) × glucose (mg dl− 1)/405.23 The presence of diabetes
mellitus (according to the American Diabetes Association
criteria24) and hypertension (blood pressure of ⩾ 140 mm Hg
systolic, ⩾ 90 mm Hg diastolic or treatment of previously diag-
nosed hypertension) was also recorded.
The FIB-4 ((age (years) × AST(U l− 1))/(thrombocytes (109 per l)
× ALT1/2 (U l− 1))) and BAAT (1 point for each item present: BMI
428 kg m− 2, age450 years, triglycerides4150 mg dl− 1 and ALT
42 × upper limit of normal) ﬁbrosis scores were calculated as
previously described.25,26
In order to validate our results, we recruited two additional
cohorts. The ﬁrst validation cohort comprised 40 patients under-
going bariatric surgery at the Ghent University Hospital between
2009 and 2017. Liver biopsy was obtained during surgery. The
second validation cohort consisted of 30 NAFLD patients followed-
up in our hepatology clinic. The majority of patients in the latter
cohort (n= 19) underwent liver biopsy and blood sampling during
the last 3 months; 11 patients were already included in a database
and had serum and liver biopsy available (collected within a 1 year
time span). The exclusion criteria and sample handling for both
cohorts were identical to the initial cohort.
The study protocol was approved by the Ethical Committee of
the Ghent University Hospital and conducted according to the
principles of the Declaration of Helsinki. Participants gave their
written informed consent, which was validated by the Ethical
Review Board.
Liver histology
Formalin-ﬁxed liver biopsies were routinely processed and stained
with hematoxylin–eosin and Masson’s trichrome. An experienced
pathologist (MP/AH) read the biopsies, blinded to the patient
characteristics. Only biopsies with at least six complete portal
tracts were deemed appropriate for adequate histological
evaluation. Histological features were scored according to the
NASH clinical research network (CRN) scoring system.27
A diagnosis of NAFLD was made if ⩾ 5% of hepatocytes contained
macrovesicular fat droplets, whereas the diagnosis of NASH was
based on the joint presence of steatosis, hepatocyte ballooning
and lobular inﬂammation.28,29 Fibrosis was evaluated using the
NASH CRN ﬁbrosis staging system.27
Measurement of serum endothelial dysfunction markers
The serum levels of several endothelial dysfunction markers were
measured using multiplex bead-based assays (Bio-Plex MAGPIX
Multiplex Reader, Bio-Rad, Temse, Belgium). VCAM-1 and inter-
cellular adhesion molecule 1 (ICAM-1) were measured with the
human cytokines 2-plex assay (#YF000000AY, Bio-Rad); the
respective sensitivity, intra- and inter-assay coefﬁcients of varia-
tion were 0.6 pg ml− 1, 6.7% and 5.5% for VCAM-1 and
2.4 pg ml− 1, 4.3% and 3.8% for ICAM-1. VEGF-A, VEGF-D, placental
growth factor (PlGF) and endoglin were measured with analytes
from the human cancer biomarker assays panel 2 (Bio-Rad). The
sensitivity, intra- and inter-assay coefﬁcients of variation were
respectively 0.4 pg ml− 1, 2.4% and 8.6% for VEGF-A; 11.5 pg ml− 1,
3.5% and 8.2% for VEGF-D, 0.2 pg ml− 1, 2.5% and 6.8% for
PlGF and 1.0 pg ml− 1, 2.9% and 9.6% for endoglin. Vascular
endothelial (VE)-cadherin serum levels were measured using a
commercially available enzyme linked immunosorbent assay
(ELISA) kit (DY938-05; R&D Systems, Abingdon, UK).
Visceral adipose tissue real-time quantitative PCR
Gene expression of the endothelial dysfunction markers was
determined in the VAT samples, obtained at the end of the
surgical intervention of 52 NAFLD patients, using real-time
quantitative PCR (RT-qPCR). First, RNA was isolated out of up to
100 μg of VAT with the RNAeasy lipid tissue mini kit (Qiagen,
Venlo, The Netherlands), according to the manufacturer’s protocol.
The concentration and quality of the resulting RNA was evaluated
using spectrophotometry and the A260/A280 ratio. cDNA synth-
esis was performed starting from 1 μg RNA, using the SensiFAST
cDNA synthesis kit (Bioline, London, UK), according to the
manufacturer’s instructions. cDNA was added to a 384-well
plate with the primers (Biolegio, Nijmegen, The Netherlands)
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(Supplementary Table 1) and Sensimix SYBR No-ROX Mastermix
(Bioline). Samples were run and analyzed using the Lightcycler 480
II (Roche, Belgium) according to manufacturer’s protocols. PCR
reactions using water instead of template showed no ampliﬁca-
tion. Measurements were performed in duplicate and Cp values
were calculated with the second derivative maximum method.
Average Cp values were normalized to the Cp of the house-
keeping genes hydroxymethylbilane synthase (HMBS) and succi-
nate dehydrogenase complex, subunit A (SDHA), which had the
most stable expression patterns among four tested housekeeping
genes, according to analysis by GeNorm (Biogazelle, Ghent,
Belgium). Fold differences for patients with NASH are expressed
relative to NAFL patients.
Statistical analysis
Statistical analysis was performed using SPSS 24.0 (SPSS Software,
IBM Corp., Armonk, NY, USA) graphs were made using Graphpad
Prism 6 (GraphPad Software Inc., La Jolla, CA, USA). Data
distribution of continuous variables was evaluated with the
Kolmogorov–Smirnov test and the appropriate parametric or
non-parametric tests were applied. A two-sided P-value ⩽ 0.05 was
considered statistically signiﬁcant. Continuous variables are
presented as median (interquartile range) or mean± s.e.m.,
depending on the normality of distribution.
After univariate analysis, signiﬁcant correlations were deter-
mined by calculating the Spearman’s rank correlation coefﬁcient.
Multivariate binary logistic regression analysis was performed to
identify independent factors associated with the presence of
signiﬁcant ﬁbrosis. Bootstrapping was performed to determine the
robustness of the regression analysis. When applicable, the
diagnostic performance was determined by constructing a
receiver-operating characteristic (ROC) curve and by calculating
the area under the ROC (AUROC) curve. Sensitivity and speciﬁcity
were calculated for the optimal cutoffs determined by ROC
analysis. The Ghent University Hospital Statistics Unit contributed
to the statistical analysis.
RESULTS
Patient characteristics
The main clinical and biochemical characteristics of the initial
study cohort are summarized in Table 1; the histological
characteristics of these patients are shown in Supplementary
Table 2.
The bariatric surgery patients were older than the control
subjects (P= 0.002) and, as expected, had a higher BMI (Po0.001),
waist circumference (Po0.001), fasting glucose (P= 0.009) and
insulin (Po0.001), ALT (Po0.001), AST (Po0.001) and GGT
(Po0.001), and had more type 2 diabetes (Po0.001) and
hypertension (Po0.001).
Patients with NASH were older than those with NAFL (P= 0.041)
and had a higher fasting glucose level (P= 0.049), and more often
had type 2 diabetes (P= 0.016), a well-known risk factor for NAFLD
progression.30 Patients with NAFL and NASH did not differ
signiﬁcantly in BMI, serum triglycerides, cholesterol, LDL choles-
terol, HDL cholesterol, fasting insulin, HOMA-IR, ALT, AST, GGT,
Table 1. Clinical and biochemical characteristics and serum endothelial dysfunction marker levels of healthy controls and obese patients with NAFL
and NASH
Characteristic Control population (n=35) NAFL (n= 24) NASH (n=37) P-value NAFL vs NASH
Age, years 34 (31–44) 43 (30–49) 46 (40–52) 0.041*$
BMI, kg m−2 23.7 (22.4–25.1) 41.5 (39.7–45.8) 40.6 (36.0–43.1) 0.100#
Waist circumference, cm 84.5 (78.6–92.9) 133 (130–140) 131 (124–141) 0.390#
Hypertension, % 14.3 63.2 80.6 0.140#
Type 2 diabetes, % 0 20.8 51.4 0.016*#
Fasting glucose, mg dl− 1 93.5 (86.1–105) 96.5 (88.5–108.8) 117 (93–150.5) 0.049*$
Fasting insulin, mU l− 1 5.4 (3.5–8.6) 12.3 (8.5–15.5) 11.6 (7.8–26.1) 0.294#
HOMA-IR 1.3 (0.8–2.1) 2.8 (2.0–4.0) 4.0 (1.9–8.6) 0.227#
Triglycerides, mg dl− 1 154 (115.5–200.7) 190.5 (145.8–224.2) 188 (147–257) 0.647§
Total Cholesterol, mg dl− 1 175.5 (143.3–202.3) 186 (164.3–206.6) 169 (141–220.5) 0.312
LDL, mg dl− 1 96 (74.8–117.3) 103.5 (78.7–126.3) 87.8 (70.8–120.5) 0.238
HDL, mg dl− 1 41 (35.8–47) 37.5 (28.3–44.0) 35 (27.5–41) 0.391§
Thrombocytes, × 103 per μl 220 (173–255) 242 (200–270) 213 (195–242) 0.113
AST, U l− 1 20 (15–25) 25 (23–30) 27 (24–42) 0.061#
ALT, U l− 1 18 (12–26) 39 (30–50) 37 (32–58) 0.647#
GGT, U l− 1 21 (15–28) 29 (21–37) 41 (25–61) 0.065#
CRP, mg l− 1 0.6 (0.4–1.1) 4.1 (2.0–6.3) 3.5 (1.3–5.8) 0.438#
CK-18 M30, U l− 1 178.8 (117–224.4) 264.3 (182.4–361.6) 277 (181.5–500.8) 0.524#
Serum endothelial dysfunction marker Control population (n=35) NAFL (n=24) NASH (n= 37) P-value overall
VEGF-A (pg ml− 1) 101.4 (75.9–126.2) 90.5 (60.8–146.6) 93.8 (52.1–148.3) 0.762
VEGF-D (pg ml− 1) 20.5 (17–27) 19.5 (15.8–24) 18 (16–23.8) 0.439
PlGF (pg ml− 1) 11.2 (8.8–13.8) 8.1 (6.5–10.4) 7.5 (6.0–10.5) 0.003**
Endoglin (pg ml− 1) 705 (389–1184) 530 (348–710) 580 (437–928) 0.335
VCAM-1 (ng ml− 1) 10.4 (8.1–12.7) 9.0 (7.9–11.6) 13.3 (7.8–15.4) 0.117
ICAM-1 (pg ml− 1) 10.7 (7.7–14.5) 10.3 (8.1–15.6) 14.2 (7.3–16.4) 0.288
VE-Cadherin (pg ml− 1) 0.25 (0.25–0.78) 0.94 (0.64–1.7) 0.99 (0.59–1.8) o0.001***
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CK-18 M30, cytokeratin-18 M30 apoptotic fragments;
CRP, C-reactive protein; GGT, γ-glutamyltransferase; HDL, high-density lipoprotein; HOMA-IR, Homeostasis Model Assessment Insulin Resistance; ICAM-1,
intercellular adhesion molecule-1; LDL, low-density lipoprotein; PlGF, placental growth factor; VCAM-1, vascular cell adhesion molecule 1; VE-Cadherin,
vascular endothelial cadherin; VEGF, vascular endothelial growth factor. Results are expressed as median (interquartile range). The Mann–Whitney U and
χ2 tests were used to compare patient characteristics between NAFL and NASH patients, or controls and NAFLD/NASH patients, whereas the Kruskal–Wallis test
was used to compare serum levels of endothelial dysfunction and angiogenic markers between controls, NAFL and NASH patients. *Po0.05; **Po0.01 and
***Po0.001 for P-values shown in the table. §Po0.05; $Po0.01 and #Po0.001 for patient characteristics between controls and patients with NAFLD/NASH.
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thrombocytes, C-reactive protein, CK-18 M30 fragments or the
presence of hypertension (Table 1).
Univariate analysis of serum markers
In univariate analysis (Table 1), vascular endothelial (VE)-cadherin
levels were higher in NAFL and NASH patients compared to the
control subjects (Po0.001). Unexpectedly, PlGF levels were lower
in NAFL and NASH patients compared to the non-obese controls
(P= 0.003). Nevertheless, there were no signiﬁcant differences in
serum markers of angiogenesis and endothelial dysfunction
between the NAFL and NASH groups.
Analysis according to the NASH CRN grading of steatosis,
inﬂammation and ballooning similarly showed no signiﬁcant
differences in any of the serum markers (Supplementary Table 3).
In contrast, serum VCAM-1 levels were higher in patients with ⩾ F2
ﬁbrosis compared to the patients with ⩽ F1 ﬁbrosis (median 14.0
and 8.7 ng ml− 1, Po0.0001) (Figure 1a). Apart from VCAM-1, only
the presence of type 2 diabetes, and serum LDL and total
cholesterol were signiﬁcantly associated with ⩾ F2 ﬁbrosis in the
obese patients (Table 2). The latter two were lower in the group
with signiﬁcant ﬁbrosis, likely due to a higher statin use in these
patients (27% vs 55% of patients, P= 0.047).
To assess the predictive value of serum VCAM-1 levels, a ROC
curve for prediction of ⩾ F2 ﬁbrosis was generated for VCAM-1
and for the FIB-4 and BAAT, two widely used non-invasive ﬁbrosis
scores. Only VCAM-1 had a good predictive value, with AUROCs
for VCAM-1, FIB-4 and BAAT of 0.80 (95% CI: 0.673–0.919,
Po0.001), 0.65 (95% CI: 0.487–0.806, P= 0.075) and 0.63 (95%
CI: 0.473–0.781, P= 0.124), respectively (Figure 1b). The best cutoff
for VCAM-1 was 13.2 ng ml− 1, with a sensitivity of 80% and
speciﬁcity of 83%. Given the prevalence of signiﬁcant ﬁbrosis of
0.33 in our population, this corresponded to a positive and
negative predictive value of 70% and 89%, respectively.
Correlations and multivariate analysis for ⩾ F2 ﬁbrosis
Variables that were signiﬁcantly associated with ⩾ F2 ﬁbrosis in
univariate analysis were further subjected to multivariate analysis.
As expected, LDL and total cholesterol correlated strongly with
each other (r= 0.886, Po0.001). Therefore, we built two separate
models. Analysis for signiﬁcant ﬁbrosis in a model combining
VCAM-1, type 2 diabetes and total cholesterol revealed that only
serum VCAM-1 and type 2 diabetes were independently
associated with signiﬁcant ﬁbrosis. Similarly, in a model combining
VCAM-1, type 2 diabetes and LDL cholesterol, only serum VCAM-1
Figure 1. (a) Serum vascular cell adhesion molecule-1 (VCAM-1) levels according to the presence or absence of signiﬁcant liver ﬁbrosis (⩾ F2
ﬁbrosis). P-values are calculated using the Mann–Whitney U-test. (b) Receiver-operating characteristic (ROC) curves for the diagnosis of
signiﬁcant ﬁbrosis in morbidly obese patients. Curves are shown for VCAM-1, FIB-4 and BAAT.
Table 2. Univariate analysis according to the presence of signiﬁcant (⩾ F2) ﬁbrosis
⩽ F1 ﬁbrosis (n= 41) ⩾ F2 ﬁbrosis (n=20) P-value
Age, years 45 (37–50) 47 (39–59) 0.162
BMI, kg m−2 40.7 (37.0–43.4) 42.3 (40.2–44.2) 0.160
Type 2 diabetes, % 26.8 65 0.005**
HOMA-IR 2.6 (1.9–4.7) 5.5 (1.8–9.0) 0.099
ALT, U l−1 41 (33–55) 36 (26–45) 0.148
AST, U l− 1 27 (24–36) 26 (21–41) 0.741
AST/ALT ratio 0.70 (0.57–0.76) 0.84 (0.59–1.02) 0.073
Thrombocytes, × 103 per μl 230 (196–270) 215 (196–240) 0.440
Total cholesterol, mg dl− 1 188.0 (161.4–222) 160.5 (119.8–197.5) 0.029*
LDL, mg dl− 1 100.5 (78.1–100.5) 86.5 (69.7–100) 0.049*
HDL, mg dl− 1 37.0 (28.5–44.5) 31.5 (24.3–37.8) 0.056
VCAM-1, ng ml− 1 8.4 (7.0–11.6) 14.0 (13.3–17.1) o0.001***
VEGF-A, pg ml− 1 87.3 (57.1–137.3) 105.3 (58.7–165.2) 0.442
Endoglin, pg ml− 1 535 (402–696) 713 (466–1035) 0.075
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; HDL, high-density lipoprotein; HOMA-IR, homeostasis
model assessment insulin resistance; LDL, low-density lipoprotein; VCAM-1, vascular cell adhesion molecule 1; VEGF, vascular endothelial growth factor. Results
are expressed as median (interquartile range). *Po0.05; **Po0.01; ***Po0.001.
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and type 2 diabetes were independently associated with
signiﬁcant ﬁbrosis (Table 3). These results remained similar after
performing bootstrapping.
Serum VCAM-1 levels correlated moderately with fasting serum
insulin levels (r=0.319, P=0.015) and thrombocytes (r=−0.266,
P=0.042), but not with other clinical and biochemical variables such
as age, BMI, HOMA-IR, AST, ALT or cholesterol (Supplementary Table
4). To conﬁrm that VCAM-1 is a predictor of signiﬁcant ﬁbrosis
independent of the patient’s characteristics and simple markers of
ﬁbrosis, we performed a multivariate analysis with age, BMI, fasting
insulin, thrombocytes, and AST/ALT ratio as co-factors. In this model,
VCAM-1 was the only variable independently associated with signiﬁ-
cant ﬁbrosis (OR=1.296 (95% CI: 1.073–1.566, P=0.007)) (Table 3).
These results did not change signiﬁcantly after bootstrapping.
Visceral adipose tissue gene expression
Recent studies have demonstrated the role of adipose tissue
inﬂammatory and adipokine gene expression in the pathogenesis
of NAFLD.31 Furthermore, adipose tissue angiogenesis may
inﬂuence insulin resistance and metabolic dysfunction.32 There-
fore, we analyzed the mRNA expression of angiogenic and
endothelial dysfunction markers in the VAT of patients under-
going bariatric surgery. When comparing NASH (n= 32) to NAFL
(n= 20) patients, endoglin (1.93 ± 0.31 fold vs NAFL, P= 0.008) and
VE-cadherin (2.66 ± 0.51-fold versus NAFL, P= 0.001) expression
was signiﬁcantly higher in NASH patients (Supplementary Table 5).
The other investigated genes showed a tendency toward
increased expression in patients with NASH, yet these differences
were not statistically signiﬁcant, probably due to the high variance
in expression levels. Endoglin and VE-cadherin also differed
signiﬁcantly when patients were stratiﬁed according to the
grading of inﬂammation (P= 0.037 and 0.002, respectively) and
ballooning (P= 0.038 and 0.020, respectively). Interestingly, only
VCAM-1 gene expression was higher in patients with liver ﬁbrosis
than in those without, and this difference was already apparent in
patients with F1 ﬁbrosis (3.25 ± 0.83-fold F1 vs F0 ﬁbrosis and
4.48 ± 1.46-fold F2 vs F0, Kruskal–Wallis P= 0.030) (Figure 2). The
serum levels and adipose tissue gene expression of these markers
did not correlate signiﬁcantly (Supplementary Table 6), indicating
that adipose tissue endothelial dysfunction does not strongly
inﬂuence the serum protein level.
External validation of VCAM-1
As the initial cohort consisted of a selected patient population,
namely obese males undergoing bariatric surgery, we set out to
validate VCAM-1 in independent patients cohorts. We recruited a
second cohort of 40 obese patients, a majority of which were
female, undergoing bariatric surgery. The patient characteristics
are shown in Supplementary Table 7. Although only three patients
had histological evidence of F2 ﬁbrosis, serum VCAM-1 levels were
higher compared to patients without signiﬁcant ﬁbrosis (13.9 in
⩽ F1 vs 21.6 ng ml− 1 in F2, P= 0.007) (Figure 3a). The AUROC for
F2 ﬁbrosis was 0.89 (95% CI: 0.71–1, P= 0.02). A low cutoff
(15.6 ng ml− 1) had a sensitivity of 100% and speciﬁcity of 68.4%,
whereas a higher cutoff of 18.4 ng ml− 1 had a sensitivity and
speciﬁcity of 66.7% and 84.2%, respectively.
Next, we recruited 30 NAFLD patients from our outpatient
hepatology clinic to test the potential of VCAM-1 as a marker in a
more general NAFLD population. The main clinical characteristics
are shown in Supplementary Table 8. VCAM-1 serum levels were
higher in patients with signiﬁcant ﬁbrosis compared to those
without (14.1 in ⩽ F1 vs 21.3 ng ml− 1 in ⩾ F2, P= 0.001)
(Figure 3b), translating into an AUROC for the prediction of ⩾ F2
ﬁbrosis of 0.85 (95% CI: 0.70–0.99, P= 0.002). The low cutoff of
15.6 ng ml− 1 had a sensitivity of 89.5% and speciﬁcity of 63.3%,
whereas the higher cutoff of 18.4 ng ml− 1 had a sensitivity and
speciﬁcity of 73.3% and 90.9%, respectively.
DISCUSSION
At present, the non-invasive diagnosis of moderate stages of ﬁbrosis
in NAFLD represents an important unmet clinical need as these
patients have a worse prognosis5 and could beneﬁt from the novel
pharmacological agents under development.33 In this study, we have
identiﬁed serum VCAM-1 as a promising marker of signiﬁcant (⩾ F2)
ﬁbrosis in a well-characterized cohort of obese men undergoing
bariatric surgery. VCAM-1 had an AUROC of 0.80 for signiﬁcant
ﬁbrosis, which was considerably higher than the AUROC of the FIB-4
and BAAT scores. Moreover, we have validated VCAM-1 in an
independent cohort of patients undergoing bariatric surgery, and in
a cohort of NAFLD patients from our outpatient clinic. VCAM-1
displayed an AUROC of respectively 0.89 and 0.85 in these cohorts,
indicating extrapolability to other patient populations.
Recent guidelines recommend a close follow-up in patients
with NASH and/or signiﬁcant (⩾ F2) liver ﬁbrosis.7 Due to the
Table 3. Multivariate analysis according to the presence of signiﬁcant
(⩾ F2) ﬁbrosis
⩾ F2 ﬁbrosis (n= 20) vs ⩽ F1 ﬁbrosis (n= 41)
OR 95% CI P-value
Model 1
Cholesterol, mg dl−1 0.987 0.970–1.005 0.159
Type 2 diabetes, % 7.190 1.564–33.049 0.011*
VCAM-1, ng ml− 1 1.372 1.128–1.668 0.002**
Model 2
LDL, mg dl− 1 0.985 0.962–1.009 0.231
Type 2 diabetes, % 5.251 1.065–25.904 0.042*
VCAM-1, ng ml− 1 1.336 1.101–1.620 0.003**
Model 3
Age, years 1.038 0.967–1.113 0.305
BMI, kg m− 2 1.020 0.906–1.149 0.738
Fasting insulin, mU l− 1 1.032 0.991–1.076 0.130
Thrombocytes,
× 103 per μl
1.000 0.983–1.017 0.994
AST/ALT ratio 1.920 0.113–32.743 0.652
VCAM-1, ng ml−1 1.296 1.073–1.566 0.007**
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotrans-
ferase; BMI, body mass index; CI, conﬁdence interval; LDL, low-density
lipoprotein; OR, odds ratio; VCAM-1, vascular cell adhesion molecule-1.
*Po0.05; **Po0.01.
Figure 2. Visceral adipose tissue vascular cell adhesion molecule 1
(VCAM-1) expression according to ﬁbrosis stage. Kruskal–Wallis
P-value was 0.030. Represented P-values were calculated using the
Mann–Whitney U-test.
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disadvantages of liver biopsy and the large population at risk for
NASH and ﬁbrosis, non-invasive diagnostic tools are increasingly
being investigated and applied in clinical practice. Nevertheless,
simple ﬁbrosis risk scores are not accurate enough to diagnose or
exclude moderate stages of ﬁbrosis, as they are tailored to
discriminate between patients with F0–F1 and F3–F4 ﬁbrosis. Liver
stiffness measurement with transient elastometry is another
attractive approach, although morbid obesity is associated with
a high technical failure rate. A meta-analysis concluded that
transient elastometry is excellent in diagnosing cirrhosis (F4) and
advanced (F3) ﬁbrosis, yet only has moderate accuracy in
signiﬁcant (F2) ﬁbrosis.34 Therefore, accurate serum markers for
⩾ F2 ﬁbrosis could aid in the identiﬁcation of patients in need of
closer follow-up.
Endothelial dysfunction and pathological angiogenesis have
been implicated in the pathogenesis of NASH. They may also
provide a link between adipose tissue dysfunction and NAFLD, as
animal studies showed that improved adipose tissue angiogenesis
through VEGF upregulation resulted in positive metabolic effects,
including improved hepatic fat accumulation.32,35 These mechan-
isms may also underlie the increased cardiovascular morbidity and
mortality in patients with NAFLD.21 We therefore evaluated the
discriminating value of endothelial dysfunction and angiogenesis
markers for NAFL, NASH and associated liver ﬁbrosis. We chose
to focus on VCAM-1, ICAM-1 and VE-cadherin because these
endothelial adhesion molecules are commonly implicated in
vascular and inﬂammatory diseases, as they mediate leukocyte
adhesion and inﬁltration.36,37 We further determined serum levels
of key molecules in physiological and/or pathological angiogen-
esis, namely VEGF-A, VEGF-D, PlGF and endoglin.38,39 Serum levels
of these proteins correlate with tumor growth and aggressiveness
in various organs, yet their expression levels in NAFLD are unclear.
Notably, serum VEGF-A had already been determined in NAFLD
patients, with conﬂicting results.38,40,41 In our cohort, serum VEFG-
A did not differ between NAFL, NASH and control patients. No
marker could predict NASH. Of note, CK-18 M30 levels also did not
differ between patients with NAFL and NASH, contradicting earlier
reports,42 yet corroborating more recent studies that casted doubt
on the potential use of CK-18 fragments as a biomarker for
NASH.34,43
On the other hand, we found that serum VCAM-1 predicted the
presence of signiﬁcant ﬁbrosis, independent from clinical and
biochemical patient characteristics. A recent paper by Yoshimura
et al.,44 in which a data mining approach to biological events was
adopted in a Japanese cohort, identiﬁed VCAM-1 as a promising
biomarker to diagnose F3–F4 ﬁbrosis. Importantly, we have
additionally shown that VCAM-1 can also reliably identify patients
with F2 ﬁbrosis, in contrast to other biomarkers, a ﬁnding we
could replicate in two validation cohorts. Interestingly, our group
previously found that VCAM-1 was an excellent predictor of
hepatopulmonary syndrome in a cohort of patients with liver
cirrhosis, with an AUROC of 0.93.45 VCAM-1 levels have also been
shown to correlate with the severity of liver cirrhosis.46 This
suggests that VCAM-1 may be a useful biomarker in patients with
chronic liver disease, both for the diagnosis of liver ﬁbrosis as well
as its associated complications. Moreover, evidence has mounted
for a role for endothelial adhesion molecules in ﬁbrotic diseases in
general, as serum VCAM-1 levels were elevated in patients with
idiopathic pulmonary ﬁbrosis and were predictive of overall and
post-transplant survival.47
Altered adipose tissue blood supply in obese subjects has also
been implemented in the pathogenesis of NAFLD as it can lead to
hypoxia, inﬂammation and insulin resistance.19,32 We aimed to
characterize VAT expression of angiogenic mediators and found
that endoglin and VE-cadherin were signiﬁcantly upregulated in
patients that had progressed to NASH. Moreover, VCAM-1
expression in VAT correlated with ﬁbrosis stage as well, and was
already upregulated in patients with minimal ﬁbrosis.
One weakness of our study is the cross-sectional design, which
means we could not collect data on the relationship between
serum VCAM-1 levels and the temporal evolution of ﬁbrosis.
Another limitation is the discrepancy in serum levels of VCAM-1
between the initial and validation cohorts, as the concentrations
were higher in the latter. Nevertheless, VCAM-1 was an adequate
predictor in each cohort and could therefore be a good candidate
to facilitate the identiﬁcation of patients with signiﬁcant ﬁbrosis
that beneﬁt from a more stringent follow-up in clinical practice.
Further large-scale validation studies will need to standardize the
analytic procedures, identify the optimal cutoff values, and
elucidate if VCAM-1 can indeed be applied as a routine screening
tool in clinical practice.
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